Acknowledgement
This work was supported by the fund from the National Natural Science Foundation of China (81971645), Guangdong Provincial People's Hospital (KY0120211130), and Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application (2022B1212010011).
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249 https://doi.org/10.3322/caac.21660
- Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol 2021;96:617-629 https://doi.org/10.1002/ajh.26151
- Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842 https://doi.org/10.1182/blood-2013-09-524108
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:601
- Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629-635 https://doi.org/10.1016/S1470-2045(08)70153-0
- Albano D, Pasinetti N, Dondi F, Giubbini R, Tucci A, Bertagna F. Prognostic role of pre-treatment metabolic parameters and sarcopenia derived by 2-[18F]-FDG PET/CT in elderly mantle cell lymphoma. J Clin Med 2022;11:1210
- Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol 2015;94:2043-2053 https://doi.org/10.1007/s00277-015-2499-4
- Gomez-Perez S, McKeever L, Sheean P. Tutorial: a step-by-step guide (version 2.0) for measuring abdominal circumference and skeletal muscle from a single cross-sectional computed-tomography image using the National Institutes of Health ImageJ. JPEN J Parenter Enteral Nutr 2020;44:419-424 https://doi.org/10.1002/jpen.1721
- Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997-1006 https://doi.org/10.1139/H08-075
- Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, et al. NCCN guidelines® insights: B-cell lymphomas, version 5.2021. J Natl Compr Canc Netw 2021;19:1218-1230 https://doi.org/10.6004/jnccn.2021.0054
- Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014;32:3048-3058 https://doi.org/10.1200/JCO.2013.53.5229
- Zhang Q, Ren J, Tan X, He M, Qiu T, Jiang L. 18 F-fluorodeoxyglucose PET/computed tomography metabolic parameters and sarcopenia in pancreatic cancer. Nucl Med Commun 2023;44:719-725 https://doi.org/10.1097/MNM.0000000000001713
- Tan X, Yuan H, Li D, Sun X, Ding C, Jiang L. Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naive patients with T-cell lymphoblastic lymphoma. Ann Hematol 2022;101:2699-2709 https://doi.org/10.1007/s00277-022-04988-4
- Yuan H, Tan X, Sun X, He L, Li D, Jiang L. Role of 18F-FDG PET/CT and sarcopenia in untreated non-small cell lung cancer with advanced stage. Jpn J Radiol 2023;41:521-530 https://doi.org/10.1007/s11604-022-01369-9
- Li D, Tan X, Yuan H, Yao X, Sun X, He L, et al. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer. Nucl Med Commun 2023;44:309-317 https://doi.org/10.1097/MNM.0000000000001669
- Albano D, Camoni L, Rinaldi R, Tucci A, Zilioli VR, Muzi C, et al. Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of 18F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation. Br J Radiol 2021;94:20200672
- Zeng X, Shi ZW, Yu JJ, Wang LF, Luo YY, Jin SM, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle 2021;12:1948-1958 https://doi.org/10.1002/jcsm.12797
- Xu XT, He DL, Tian MX, Wu HJ, Jin X. Prognostic value of sarcopenia in patients with diffuse large B-cell lymphoma treated with R-CHOP: a systematic review and meta-analysis. Front Nutr 2022;9:816883
- Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, et al. Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans. J Natl Cancer Inst 2016;108:djw145
- Lucijanic M, Huzjan Korunic R, Sedinic M, Kusec R, Pejsa V. More pronounced muscle loss during immunochemotherapy is associated with worse clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features. Ther Clin Risk Manag 2021;17:1037-1044 https://doi.org/10.2147/TCRM.S323749
- Bas V, Umit EG, Korkmaz U, Baysal M, Karaman Gulsaran S, Demirci U, et al. Sarcopenia in Hodgkin's lymphoma evaluated with 18-FDG PET/CT, focus on age, performance, and treatment. Support Care Cancer 2021;29:2475-2480 https://doi.org/10.1007/s00520-020-05772-8
- Park S, Han B, Cho JW, Woo SY, Kim S, Kim SJ, et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 2014;66:225-233 https://doi.org/10.1080/01635581.2014.867065
- Chu MP, Lieffers J, Ghosh S, Belch A, Chua NS, Fontaine A, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. J Cachexia Sarcopenia Muscle 2017;8:298-304 https://doi.org/10.1002/jcsm.12161
- Besutti G, Massaro F, Bonelli E, Braglia L, Casali M, Versari A, et al. Prognostic impact of muscle quantity and quality and fat distribution in diffuse large B-cell lymphoma patients. Front Nutr 2021;8:620696
- Albano D, Dondi F, Ravanelli M, Tucci A, Farina D, Giubbini R, et al. Prognostic role of "radiological" sarcopenia in lymphoma: a systematic review. Clin Lymphoma Myeloma Leuk 2022;22:e340-e349 https://doi.org/10.1016/j.clml.2021.11.006
- Camus V, Lanic H, Kraut J, Modzelewski R, Clatot F, Picquenot JM, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 2014;93:9-18 https://doi.org/10.1111/ejh.12285
- Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2014;55:817-823 https://doi.org/10.3109/10428194.2013.816421
- Iltar U, Sozel H, Sozel YK, Atas, u, Yucel OK, Salim O, et al. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy. Leuk Lymphoma 2021;62:1098-1106 https://doi.org/10.1080/10428194.2020.1856833
- Go SI, Kim HG, Kang MH, Park S, Lee GW. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma. BMC Cancer 2020;20:439
- Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276-3284 https://doi.org/10.1182/blood-2011-09-380949
- Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer 2009;45:1017-1027 https://doi.org/10.1016/j.ejca.2008.11.008
- Zhang YY, Song L, Zhao MX, Hu K. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUVmax. Cancer Med 2019;8:5137-5147 https://doi.org/10.1002/cam4.2284